A Phase 3, Multicenter, Open-label, Randomized Study of Nab-Paclitaxel Plus Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Subjects With Surgically Resected Pancreatic Adenocarcinoma
收藏DataCite Commons2026-03-06 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00012815/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to compare whether there is a delay or prevention of recurrence or death in participants with surgically removed pancreatic cancer who then take nab-Paclitaxel in combination with gemcitabine compared to those who take gemcitabine alone.
提供机构：
Vivli
创建时间：
2026-03-06
